Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Todd Neale

November 09, 2022

Presentation AHA 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presenter: David E. Kandzari

November 07, 2022

Presentation TCT 2022

It’s Time We Had These Devices Approved and Reimbursed

Presenter: David E. Kandzari

September 18, 2022

Presentation TCT 2022

Update on the SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation)

Presenter: David Kandzari

September 17, 2022

Podcast TCTMD Talking Points

The OPTIMUM Trial

June 22, 2022

News Conference News EuroPCR 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Yael L. Maxwell

May 17, 2022

News Conference News EuroPCR 2022

Registry Data Hint at MACE Benefit With Renal Denervation

Michael O'Riordan

May 17, 2022

Presentation Fellows 2022

Case and Technique Reviews: High-Risk PCI and Cardiogenic Shock – The Role of Hemodynamic Support

Presenter: David Kandzari

May 07, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

Presentation CTO 2022

Surgical Turndowns: What We Know and What We Don’t

Presenter: David Kandzari

February 25, 2022

Presentation CTO 2022

CTO Regulatory Studies in Context

Presenter: David Kandzari

February 24, 2022

Advertisement

Reduction in BP Drives Treatment Preference for Hypertensive Patients

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

It’s Time We Had These Devices Approved and Reimbursed

Update on the SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation)

The OPTIMUM Trial

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Registry Data Hint at MACE Benefit With Renal Denervation

Case and Technique Reviews: High-Risk PCI and Cardiogenic Shock – The Role of Hemodynamic Support

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Surgical Turndowns: What We Know and What We Don’t

CTO Regulatory Studies in Context

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content